Study to assess ability of GAL-101 eye drops in slowing or stopping the growth of geographic atrophy, a severe form of age-related macular ...

Blarcamesine: Potential novel oral treatment to target upstream Alzheimer's disease pathology through autophagy enhancement Submission based on favorable ANAVEX®2-73-AD-004 trial results in patients ...

On December 9, 2024, Anavex announced its upcoming presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial at the J.P. Morgan 2025 Healthcare ...

Blarcamesine is an orally once daily administered small molecule for the potential treatment of patients with Alzheimer's disease.

From new surgical techniques and treatments to studies on neurodegenerative disease, here are five of the top brain science stories from this year. In the progression of Alzheimer's disease a ...

According to Raj Dasgupta, MD, chief medical advisor for Garage Gym Reviews, one of the most common side effects of taking ...

Research Focus Areas The new initiative will focus on three primary research areas: Neurological health: Investigating Klotho's neuroprotective effects and its potential to slow cognitive decline in ...

The U.S. Preventive Services Task Force released a draft recommendation advising against using vitamin D to prevent falls and ...

Discover the truth behind Alpha Bites reviews—is this male health booster the game-changer you've been waiting for or just ...

Ash gourd has a very low glycemic index and hence prevents sugar spikes. This is a beneficial beverage option for people with type 2 diabetes and other me ...

StockNews.com began coverage on shares of MediciNova (NASDAQ:MNOV – Free Report) in a research note issued to investors on Tuesday morning. The brokerage issued a hold rating on the biopharmaceutical ...

After 16 years of toilsome studies, Dr Nene Ahidjo on November 27, 2024 defended a PhD in Neuropharmacology. Fulfilling her ...